First Biosimilar Approved to Treat Multiple Sclerosis
FRIDAY, Aug. 25, 2023 (HealthDay News) — The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announc…
Learn MoreMore Biosimilars Marketed in Germany, Switzerland Than U.S.
FRIDAY, Dec. 2, 2022 (HealthDay News) — More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.D…
Learn More